Antihypertensive therapy and endothelial function

Sunil Nadar, Andrew D. Blann, Gregory Y H Lip

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

The benefits of treating hypertension in terms of reduction of morbidity and mortality are well established. However, it is debatable whether this benefit is derived entirely from the effects of a reduced blood pressure or whether these agents exert effects over and above blood pressure reduction on the endothelium. Hypertension is associated with adverse changes (whether damage or dysfunction) in the endothelium. Indeed, endothelial damage/dysfunction has have been demonstrated to be a reliable prognostic indicator of future cardiovascular events in hypertension. Of the various drug classes, calcium channel blockers and the ACE inhibitors have significant direct effects on the endothelium. This is in contrast to the beta blockers and alpha adrenergic blockers that appear to indirectly influence endothelial function solely as a result of lowered blood pressure. Antioxidants may have a beneficial effect on endothelial function as well, although their clinical use does not seem to translate into clinical benefit.

Original languageEnglish
Pages (from-to)3607-3614
Number of pages8
JournalCurrent Pharmaceutical Design
Volume10
Issue number29
DOIs
Publication statusPublished - 2004

Fingerprint

Antihypertensive Agents
Endothelium
Blood Pressure
Hypertension
Adrenergic alpha-Antagonists
Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Therapeutics
Antioxidants
Morbidity
Mortality
Pharmaceutical Preparations

Keywords

  • Antihypertensive treatment
  • Endothelial function

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Antihypertensive therapy and endothelial function. / Nadar, Sunil; Blann, Andrew D.; Lip, Gregory Y H.

In: Current Pharmaceutical Design, Vol. 10, No. 29, 2004, p. 3607-3614.

Research output: Contribution to journalReview article

Nadar, Sunil ; Blann, Andrew D. ; Lip, Gregory Y H. / Antihypertensive therapy and endothelial function. In: Current Pharmaceutical Design. 2004 ; Vol. 10, No. 29. pp. 3607-3614.
@article{661566c0a4a04de3be229e275286eed0,
title = "Antihypertensive therapy and endothelial function",
abstract = "The benefits of treating hypertension in terms of reduction of morbidity and mortality are well established. However, it is debatable whether this benefit is derived entirely from the effects of a reduced blood pressure or whether these agents exert effects over and above blood pressure reduction on the endothelium. Hypertension is associated with adverse changes (whether damage or dysfunction) in the endothelium. Indeed, endothelial damage/dysfunction has have been demonstrated to be a reliable prognostic indicator of future cardiovascular events in hypertension. Of the various drug classes, calcium channel blockers and the ACE inhibitors have significant direct effects on the endothelium. This is in contrast to the beta blockers and alpha adrenergic blockers that appear to indirectly influence endothelial function solely as a result of lowered blood pressure. Antioxidants may have a beneficial effect on endothelial function as well, although their clinical use does not seem to translate into clinical benefit.",
keywords = "Antihypertensive treatment, Endothelial function",
author = "Sunil Nadar and Blann, {Andrew D.} and Lip, {Gregory Y H}",
year = "2004",
doi = "10.2174/1381612043382800",
language = "English",
volume = "10",
pages = "3607--3614",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "29",

}

TY - JOUR

T1 - Antihypertensive therapy and endothelial function

AU - Nadar, Sunil

AU - Blann, Andrew D.

AU - Lip, Gregory Y H

PY - 2004

Y1 - 2004

N2 - The benefits of treating hypertension in terms of reduction of morbidity and mortality are well established. However, it is debatable whether this benefit is derived entirely from the effects of a reduced blood pressure or whether these agents exert effects over and above blood pressure reduction on the endothelium. Hypertension is associated with adverse changes (whether damage or dysfunction) in the endothelium. Indeed, endothelial damage/dysfunction has have been demonstrated to be a reliable prognostic indicator of future cardiovascular events in hypertension. Of the various drug classes, calcium channel blockers and the ACE inhibitors have significant direct effects on the endothelium. This is in contrast to the beta blockers and alpha adrenergic blockers that appear to indirectly influence endothelial function solely as a result of lowered blood pressure. Antioxidants may have a beneficial effect on endothelial function as well, although their clinical use does not seem to translate into clinical benefit.

AB - The benefits of treating hypertension in terms of reduction of morbidity and mortality are well established. However, it is debatable whether this benefit is derived entirely from the effects of a reduced blood pressure or whether these agents exert effects over and above blood pressure reduction on the endothelium. Hypertension is associated with adverse changes (whether damage or dysfunction) in the endothelium. Indeed, endothelial damage/dysfunction has have been demonstrated to be a reliable prognostic indicator of future cardiovascular events in hypertension. Of the various drug classes, calcium channel blockers and the ACE inhibitors have significant direct effects on the endothelium. This is in contrast to the beta blockers and alpha adrenergic blockers that appear to indirectly influence endothelial function solely as a result of lowered blood pressure. Antioxidants may have a beneficial effect on endothelial function as well, although their clinical use does not seem to translate into clinical benefit.

KW - Antihypertensive treatment

KW - Endothelial function

UR - http://www.scopus.com/inward/record.url?scp=6344230102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6344230102&partnerID=8YFLogxK

U2 - 10.2174/1381612043382800

DO - 10.2174/1381612043382800

M3 - Review article

VL - 10

SP - 3607

EP - 3614

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 29

ER -